[1]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139-141.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(13):139-141.[doi:10.3969/j.issn.1006-1959.2018.13.041]
点击复制

阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年13期
页码:
139-141
栏目:
药物与临床
出版日期:
2018-07-01

文章信息/Info

Title:
Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease
文章编号:
1006-1959（2018）13-0139-03
作者:
王 毅
蕲春县人民医院心血管内科，湖北 蕲春 435300
Author(s):
WANG Yi
Department of Cardiovascular Medicine,Qichun People’s Hospital,Qichun 435300,Hubei,China
关键词:
冠心病; 阿托伐他汀; 曲美他嗪
Keywords:
Key words：Coronary atherosclerotic heart disease; Atto vastatin; Trimetazidine
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2018.13.041
文献标志码:
A
摘要:
目的 分析阿托伐他汀+曲美他嗪治疗冠心病的临床疗效。方法 选取2016年1月~2017年12月来我院就诊的86例冠心病患者，随机分为对照组和研究组，每组43例。两组患者均接受常规治疗，对照组在此基础上服用盐酸曲美他嗪片，研究组服用阿托伐他汀钙片+盐酸曲美他嗪片，观察两组患者治疗总有效率、血脂指标、常规指标及不良反应的发生情况。结果 研究组治疗总有效率为93.02%，高于对照组的76.74%，差异具有统计学意义（P＜0.05）。研究组血脂指标及常规指标优于对照组，差异有统计学意义（P＜0.05）。研究组不良反应发生率为4.65%，低于对照组的18.60%，差异有统计学意义（P＜0.05）。结论 阿托伐他汀联合曲美他嗪治疗冠心病疗效显著，安全性高，值得推广应用。
Abstract:
Abstract：Objective To analyze the clinical efficacy of Atto vastatin combined with trimetazidine in the treatment of coronary atherosclerotic heart disease.Methods 86 patients with coronary atherosclerotic heart disease from January 2016 to December 2017 were randomly divided into control group(n=43)and study group(n=43).Patients in both groups received routine treatment,the control group took trimetazidine hydrochloride tablets on this basis,and the study group took Atto vastatin calcium+trimetazidine hydrochloride tablets.The total effective rate and blood lipid index of the two groups were observed as well as routine indicators and adverse reactions.Results The total effective rate of the study group was 93.02%,which was higher than that of the control group 76.74%,the difference was statistically significant(P<0.05).The blood lipid index and routine index in the study group were better than those in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 4.65%,which was significantly lower than that in the control group 18.60%,the difference was statistically significant(P<0.05).Conclusion Atto vastatin combined with trimetazidine is effective and safe in the treatment of coronary atherosclerotic heart disease.

参考文献/References:

[1]王玉竹.阿托伐他汀联合曲美他嗪治疗冠心病的效果评价[J].当代医学,2016,22(36):77-78. [2]冯永,赵辉,白秋江,等.阿托伐他汀+曲美他嗪共同治疗冠心病的效果评价[J].中国煤炭工业医学杂志,2017,20(9):1014-1016. [3]马欣.阿托伐他汀联合曲美他嗪治疗冠心病的效果观察[J].中国继续医学教育,2016,10(24):157-158. [4]宋金梅,魏旭明,焦全德,等.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果观察[J].医学理论与实践,2016,29(11):1443-1445. [5]夏志琦,彭长农,孙晓红,等.阿托伐他汀联合曲美他嗪治疗冠心病的临床研究[J].中国实用医药,2016,11(15):142-143. [6]林晨晖.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果[J].中外医学研究,2016,14(33):38-40. [7]李玲,郭家全,李强,等.阿托伐他汀与曲美他嗪联用治疗冠心病的疗效评价[J].中国继续医学教育,2016,8(8):154-155.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Journal of Medical Information,2018,31(13):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Journal of Medical Information,2018,31(13):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Journal of Medical Information,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Journal of Medical Information,2018,31(13):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(13):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Journal of Medical Information,2018,31(13):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Journal of Medical Information,2018,31(13):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Journal of Medical Information,2018,31(13):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(13):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Journal of Medical Information,2022,35(13):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
[11]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(13):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[12]师存莉,陈 蓉.阿托伐他汀联合冠心舒通胶囊对糖尿病合并冠心病患者心律失常的疗效及对血脂与凝血功能的影响[J].医学信息,2022,35(06):159.[doi:10.3969/j.issn.1006-1959.2022.06.041]
　SHI Cun-li,CHEN Rong.Effect of Atorvastatin Combined with Guanxinshutong Capsule on Arrhythmia and Blood Lipid and Coagulation Function in Diabetic Patients with Coronary Heart Disease[J].Journal of Medical Information,2022,35(13):159.[doi:10.3969/j.issn.1006-1959.2022.06.041]

更新日期/Last Update: 2018-07-01